HedgeChatter

  • Home /
  • Tag Archives

RPRXW

Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal®

[at noodls] – Contact: Repros Therapeutics Inc. … This is an abstract of the original noodl. To continue reading this document, click here for the original version. moreView todays social media effects on RPRXWView the latest stocks trending across Twitter. Click to view dashboardSee who Repros is hiring next, click here to view […]

March 28, 2013 Bystocknews , Comments Off on Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal® read more

FDA Grants Repros An End of Phase 2 Meeting in Late May to Discuss Proellex®-V Phase 3 Study Design

[at noodls] – Contact: Repros Therapeutics Inc….This is an abstract of the original noodl. To continue reading this document, click here for the original version. moreView todays social media effects on RPRXWView the latest stocks trending across Twitter. Click to view dashboardSee who Repros is hiring next, click here to view […]

February 28, 2013 Bystocknews , Comments Off on FDA Grants Repros An End of Phase 2 Meeting in Late May to Discuss Proellex®-V Phase 3 Study Design read more

Repros Reports FDA Recommends Pivotal Study ZA-301 of Androxal® to be Completed as Originally Planned

[at noodls] – Contact: Repros Therapeutics Inc….This is an abstract of the original noodl. To continue reading this document, click here for the original version. moreView todays social media effects on RPRXWView the latest stocks trending across Twitter. Click to view dashboardSee who Repros is hiring next, click here to view […]

February 21, 2013 Bystocknews , Comments Off on Repros Reports FDA Recommends Pivotal Study ZA-301 of Androxal® to be Completed as Originally Planned read more

Repros Therapeutics Corporate Update

[at noodls] – Contact: Repros Therapeutics Inc….This is an abstract of the original noodl. To continue reading this document, click here for the original version. moreView todays social media effects on RPRXWView the latest stocks trending across Twitter. Click to view dashboardSee who Repros is hiring next, click here to view […]

February 11, 2013 Bystocknews , Comments Off on Repros Therapeutics Corporate Update read more

ZA-301 Slide Presentation (PDF)

[at noodls] – ZA-301 Site 9 Evaluation Blinded Assessment Repros Disclaimer Any statements made by the Company that are not historical facts contained in this release are forward-looking statements that involve risks … moreView todays social media effects on RPRXWView the latest stocks trending across Twitter. Click to view dashboardSee who Repros is hiring next, click here to view […]

January 29, 2013 Bystocknews , Comments Off on ZA-301 Slide Presentation (PDF) read more

Repros Updates Guidance for Top Line Results from First Pivotal Androxal® Study to Q3 2013

[at noodls] – Contact: Repros Therapeutics Inc….This is an abstract of the original noodl. To continue reading this document, click here for the original version. moreView todays social media effects on RPRXWView the latest stocks trending across Twitter. Click to view dashboardSee who Repros is hiring next, click here to view […]

January 28, 2013 Bystocknews , Comments Off on Repros Updates Guidance for Top Line Results from First Pivotal Androxal® Study to Q3 2013 read more

Repros’ Proellex®-V Topline Analysis Suggests 12 MG Dose Effective and Well Tolerated in Phase 2 for Uterine Fibroids

[at noodls] – Contact: Repros Therapeutics Inc….This is an abstract of the original noodl. To continue reading this document, click here for the original version. moreView todays social media effects on RPRXWView the latest stocks trending across Twitter. Click to view dashboardSee who Repros is hiring next, click here to view […]

January 4, 2013 Bystocknews , Comments Off on Repros’ Proellex®-V Topline Analysis Suggests 12 MG Dose Effective and Well Tolerated in Phase 2 for Uterine Fibroids read more

Repros Presents Androxal® and Proellex® Clinical Updates at The Lazard Capital Markets 9th Annual Healthcare Conference

[at noodls] – Contact: Repros Therapeutics Inc….This is an abstract of the original noodl. To continue reading this document, click here for the original version. moreView todays social media effects on RPRXWView the latest stocks trending across Twitter. Click to view dashboard […]

November 16, 2012 Bystocknews , Comments Off on Repros Presents Androxal® and Proellex® Clinical Updates at The Lazard Capital Markets 9th Annual Healthcare Conference read more

Repros to Present Androxal® and Proellex® Clinical Updates at The Lazard Capital Markets 9th Annual Healthcare Conference

[at noodls] – Contact: Repros Therapeutics Inc….This is an abstract of the original noodl. To continue reading this document, click here for the original version. moreView todays social media effects on RPRXWView the latest stocks trending across Twitter. Click to view dashboard […]

November 5, 2012 Bystocknews , Comments Off on Repros to Present Androxal® and Proellex® Clinical Updates at The Lazard Capital Markets 9th Annual Healthcare Conference read more